Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Pain control with zoledronic acid in patients with breast cancer and metastatic bone disease

Pain control with zoledronic acid in patients with breast cancer and metastatic bone disease cancer patients. Bisphosphonates are recommended in treating skeletal complications and there is evidence that they also control pain. Objective: To investigate the effects of zoledronic acid, a potent nitrogen-containing bisphosphonate, in reducing pain in patients with advanced breast cancer and bone metastases. Patients and methods: Thirty-two patients (age range 37–79 years, median 56 years) with histologically proven breast cancer and bone metastases received a 15-minute infusion of zoledronic acid 4mg every 4 weeks for a mean of eight cycles (range 1–13) in a phase II pilot study. The primary efficacy endpoint was the control of pain as determined by changes in pain and analgesic scores. Results: Zoledronic acid substantially reduced pain scores compared with baseline, with over 80% of patients reporting mild or no pain at the end of the trial (82% had moderate to very severe pain on entry). The percentage of patients requiring no analgesics increased from 9% to 35% following zoledronic acid treatment. At baseline, 47% of patients required opioids to control pain, whereas 27% required opioids at the end of the trial. Zoledronic acid appeared to be well tolerated, with no patients reporting serious adverse events. Conclusion: These results support previous data indicating that zoledronic http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Pain control with zoledronic acid in patients with breast cancer and metastatic bone disease

Loading next page...
 
/lp/springer-journals/pain-control-with-zoledronic-acid-in-patients-with-breast-cancer-and-yZehBx2t8h
Publisher
Springer Journals
Copyright
Copyright © 2004 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200403040-00005
Publisher site
See Article on Publisher Site

Abstract

cancer patients. Bisphosphonates are recommended in treating skeletal complications and there is evidence that they also control pain. Objective: To investigate the effects of zoledronic acid, a potent nitrogen-containing bisphosphonate, in reducing pain in patients with advanced breast cancer and bone metastases. Patients and methods: Thirty-two patients (age range 37–79 years, median 56 years) with histologically proven breast cancer and bone metastases received a 15-minute infusion of zoledronic acid 4mg every 4 weeks for a mean of eight cycles (range 1–13) in a phase II pilot study. The primary efficacy endpoint was the control of pain as determined by changes in pain and analgesic scores. Results: Zoledronic acid substantially reduced pain scores compared with baseline, with over 80% of patients reporting mild or no pain at the end of the trial (82% had moderate to very severe pain on entry). The percentage of patients requiring no analgesics increased from 9% to 35% following zoledronic acid treatment. At baseline, 47% of patients required opioids to control pain, whereas 27% required opioids at the end of the trial. Zoledronic acid appeared to be well tolerated, with no patients reporting serious adverse events. Conclusion: These results support previous data indicating that zoledronic

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

References